Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR2 | Q92731 | 1/20 | 0.52 |
| ▸ | NR1H2 | P55055 | 2/20 | 0.51 |
| ▸ | MAPT | P10636 | 2/20 | 0.51 |
| ▸ | HPGDS | O60760 | 2/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.45 |
| ▸ | SLC34A1 | Q06495 | 1/20 | 0.42 |
| ▸ | PDK2 | Q15119 | 3/20 | 0.41 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.40 |
| ▸ | NAMPT | P43490 | 1/20 | 0.39 |
| ▸ | PARP1 | P09874 | 1/20 | 0.39 |
| ▸ | TNKS2 | Q9H2K2 | 1/20 | 0.39 |
| ▸ | PARP2 | Q9UGN5 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29581700 | 0.92 | ESR2 (0.47) | ESR2NR1H2MAPTHPGDSMAPK1 | |
| SCHEMBL15825114 | 0.89 | ESR2 (0.52) | ESR2NR1H2MAPTHPGDSMAPK1 | |
| SCHEMBL20364274 | 0.87 | NR1H2 (0.46) | ESR2NR1H2MAPTHPGDSMAPK1 | |
| SCHEMBL16220602 | 0.85 | ESR2 (0.51) | ESR2NR1H2MAPTHPGDSMAPK1 | |
| SCHEMBL17327937 | 0.85 | ESR2 (0.51) | ESR2NR1H2MAPTHPGDSMAPK1 | |
| SCHEMBL1881390 | 0.84 | ESR2 (0.47) | ESR2NR1H2MAPTHPGDSMAPK1 | |
| SCHEMBL15340725 | 0.83 | ESR2 (0.49) | ESR2NR1H2MAPTHPGDSMAPK1 | |
| SCHEMBL16217193 | 0.82 | HPGDS (0.52) | ESR2NR1H2MAPTHPGDSMAPK1 | |
| SCHEMBL30171269 | 0.82 | ESR2 (0.48) | ESR2NR1H2MAPTHPGDSMAPK1 | |
| SCHEMBL5777653 | 0.82 | ESR2 (0.46) | ESR2NR1H2MAPTHPGDSMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250092065-A1 | 2-(INDAZOL-5-YL)-6-(PIPERIDIN-4-YL)-1,7-NAPHTHYRIDINE DERIVATIVES AND RELATED COMPOUNDS AS MODULATORS FOR SPLICING NUCLEIC ACIDS AND FOR THE TREATMENT OF PROLIFERATIVE DISEASES | REMIX THERAPEUTICS INC (US) | 2025-03-20 | — | — | US | disclosed |
| US-11802131-B2 | Glutarimides for medical treatment | C4 THERAPEUTICS, INC. (US) | 2023-10-31 | — | — | US | disclosed |
| WO-2023133217-A1 | 2-(INDAZOL-5-YL)-6-(PIPERIDIN-4-YL)-1,7-NAPHTHYRIDINE DERIVATIVES AND RELATED COMPOUNDS AS MODULATORS FOR SPLICING NUCLEIC ACIDS AND FOR THE TREATMENT OF PROLIFERATIVE DISEASES | REMIX THERAPEUTICS INC. (US) | 2023-07-13 | — | — | WO | disclosed |
| WO-2023029943-A1 | AROMATIC HETEROCYCLIC COMPOUND, PREPARATION METHOD THEREFOR AND USE THEREOF | 星药科技(北京)有限公司 | 2023-03-09 | — | — | WO | disclosed |
| CN-110167937-B | Bicyclic bis-heteroaryl derivatives as modulators of protein aggregation | UCB生物制药私人有限公司 | 2022-03-29 | — | — | CN | disclosed |
| EP-3573986-B1 | BICYCLIC BIS-HETEROARYL DERIVATIVES AS MODULATORS OF PROTEIN AGGREGATION | UCB Biopharma SRL (BE) | 2021-05-26 | — | — | EP | disclosed |
| EP-3573986-B1 | BICYCLIC BIS-HETEROARYL DERIVATIVES AS MODULATORS OF PROTEIN AGGREGATION | UCB Biopharma SRL (BE) | 2021-05-26 | — | — | EP | disclosed |
| US-10889584-B2 | Bicyclic bis-heteroaryl derivatives as modulators of protein aggregation | UCB Biopharma SRL (BE) | 2021-01-12 | — | — | US | disclosed |
| US-10889584-B2 | Bicyclic bis-heteroaryl derivatives as modulators of protein aggregation | UCB Biopharma SRL (BE) | 2021-01-12 | — | — | US | disclosed |
| WO-2018138088-A1 | BICYCLIC BIS-HETEROARYL DERIVATIVES AS MODULATORS OF PROTEIN AGGREGATION | UCB BIOPHARMA SPRL (BE) | 2018-08-02 | — | — | WO | disclosed |
| US-20170210751-A1 | PRMT5 INHIBITORS AND USES THEREOF | Epizyme, Inc. (US) | 2017-07-27 | — | — | US | disclosed |
| EP-3160466-A2 | PRMT5 INHIBITORS AND USES THEREOF | Epizyme, Inc. (US) | 2017-05-03 | — | — | EP | disclosed |
| US-9296761-B2 | Triazine derivatives | PFIZER INC. (US) | 2016-03-29 | — | — | US | disclosed |
| WO-2015200677-A2 | PRMT5 INHIBITORS AND USES THEREOF | Epizyme, Inc. (US) | 2015-12-30 | — | — | WO | disclosed |
| WO-2015200677-A2 | PRMT5 INHIBITORS AND USES THEREOF | Epizyme, Inc. (US) | 2015-12-30 | — | — | WO | disclosed |
| US-20150353579-A1 | Triazine Derivatives | PFIZER (US) | 2015-12-10 | — | — | US | disclosed |
| US-9145427-B2 | Triazine derivatives | PFIZER INC. (US) | 2015-09-29 | — | — | US | disclosed |
| US-20150080401-A1 | Triazine Derivatives | PFIZER (US) | 2015-03-19 | — | — | US | disclosed |
| US-8933224-B2 | Triazine derivatives | PFIZER INC. (US) | 2015-01-13 | — | — | US | disclosed |
| US-20140329820-A1 | Triazine Derivatives | PFIZER INC. (US) | 2014-11-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140329820-A1 | Triazine Derivatives | PDE12, PDE5A, PDE10A | ESR2 2152/4885NR1H2 869/4885MAPT 3633/4885 |
| US-20250092065-A1 | 2-(INDAZOL-5-YL)-6-(PIPERIDIN-4-YL)-1,7-NAPHTHYRIDINE DERIVATIVES AND RELATED COMPOUNDS AS MODULATORS FOR SPLICING NUCLEIC ACIDS AND FOR THE TREATMENT OF PROLIFERATIVE DISEASES | SNRPA, SNRPB2, HNRNPAB | ESR2 934/4885NR1H2 1529/4885MAPT 2800/4885 |
| US-10889584-B2 | Bicyclic bis-heteroaryl derivatives as modulators of protein aggregation | PARK7, HTT, SNCA | ESR2 3524/4885NR1H2 3348/4885MAPT 5/4885 |
| US-11802131-B2 | Glutarimides for medical treatment | CRBN, GCDH, GCLC | ESR2 1069/4885NR1H2 1354/4885MAPT 2160/4885 |
| US-20150353579-A1 | Triazine Derivatives | PDE12, PDE5A, PDE10A | ESR2 2152/4885NR1H2 869/4885MAPT 3633/4885 |
| US-20170210751-A1 | PRMT5 INHIBITORS AND USES THEREOF | PRMT5, PRMT1, PRMT6 | ESR2 2678/4885NR1H2 914/4885MAPT 3461/4885 |
| US-20150080401-A1 | Triazine Derivatives | PDE12, PDE5A, PDE10A | ESR2 2152/4885NR1H2 869/4885MAPT 3633/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.